BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26031546)

  • 1. Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
    Reagan PM; Friedberg JW
    Curr Treat Options Oncol; 2015 Jul; 16(7):32. PubMed ID: 26031546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
    Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC
    Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
    Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR
    Value Health; 2015 Mar; 18(2):189-97. PubMed ID: 25773554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low grade lymphoma: research progress and questions about treatment].
    Ishizawa K
    Rinsho Ketsueki; 2015 Oct; 56(10):2039-46. PubMed ID: 26458443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized management of follicular lymphoma.
    Bai B; Huang HQ
    Chin Clin Oncol; 2015 Mar; 4(1):7. PubMed ID: 25841714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?
    Kahl B
    Hematology Am Soc Hematol Educ Program; 2012; 2012():433-8. PubMed ID: 23233615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
    Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
    Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era.
    Tari A; Asaoku H; Takata K; Fujimori S; Tanaka S; Fujihara M; Koga T; Yoshino T
    Scand J Gastroenterol; 2016 Mar; 51(3):321-8. PubMed ID: 26382560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
    Prica A; Chan K; Cheung M
    Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.
    Kahl BS; Hong F; Williams ME; Gascoyne RD; Wagner LI; Krauss JC; Habermann TM; Swinnen LJ; Schuster SJ; Peterson CG; Sborov MD; Martin SE; Weiss M; Ehmann WC; Horning SJ
    J Clin Oncol; 2014 Oct; 32(28):3096-102. PubMed ID: 25154829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?
    Rueda A; Casanova M; Redondo M; Pérez-Ruiz E; Medina-Pérez A
    BMC Cancer; 2012 May; 12():210. PubMed ID: 22650448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
    Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova J; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Leuk Lymphoma; 2016 May; 57(5):1094-103. PubMed ID: 26293000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy in follicular lymphoma.
    Illidge T; Morschhauser F
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
    Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
    J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
    Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
    Br J Haematol; 2016 Mar; 172(5):724-34. PubMed ID: 26729445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is observation dead in follicular lymphoma? Still appropriate.
    Jacobson CA; Freedman AS
    J Natl Compr Canc Netw; 2015 Mar; 13(3):367-70. PubMed ID: 25736012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.